What is it about?
The study enrolled 111 subjects randomized into two groups: study group, patients with the angioedema as a secondary side effect to enalapril; and control group, patients without adverse drug reaction. All patients underwent pharmacogenetic testing. Results: An association between the development of the angioneurotic edema and the genotypes AA rs2306283 of gene SLCO1B1, TT rs4459610 of gene ACE, and CC rs1799722 of gene BDKRB2 in patients was revealed.
Featured Image
Photo by freestocks on Unsplash
Why is it important?
Angioneurotic edema is the most dangerous complication in angiotensin-converting enzyme inhibitors (ACEIs) therapy. Based on the current data, the clinical and genetic predictors of angioedema development are still understudied, which demonstrates the relevance of this study
Perspectives
The findings justify further investigations of the revealed genetic predictors of angioedema with larger-size patient populations.
Ivan Sychev
Russian Medical Academy of Continuous Professional Education
Read the Original
This page is a summary of: Pharmacogenetic markers of development of angioneurotic edema as a secondary side effect to enalapril in patients with essential arterial hypertension, International Journal of Risk & Safety in Medicine, September 2023, IOS Press,
DOI: 10.3233/jrs-230006.
You can read the full text:
Contributors
The following have contributed to this page
